Pharma giants lose out in urological disorders market
Major pharmaceutical companies are predicted to lose their footing in the urological disorders market by 2017, a new report by pharmaceutical intelligence expert GBI Research has found.
The new report revealed that the global urological disorders market will witness multiple patent expiries between 2009 and 2017.
They include several of the top-selling blockbuster drugs in the urinary incontinence (UI), benign prostatic hyperplasia (BPH), urinary tract Infection (UTI) and interstitial cystitis (IC) markets.
To read the latest edition of Healthcare Global, click here
- Watchdog approves Vinnie Jones’ hands-only CPR ad
- 30 second eye test could help prevent heart attacks
- New plasma flashlight can kill bacteria and germs
Such patent expirations of leading drugs are expected to erode the 72 percent market share held in 2010 by the top five players in the field, namely Johnson & Johnson, Boehringer Ingelheim, Astellas Pharma, Pfizer, and GlaxoSmithKline (GSK).
Important drugs that have recently lost patent protection include Boehringer Ingelheim and Astellas Pharma’s Flomax (tamsulosin) in 2009 and Johnson & Johnson’s Levaquin (levofloxacin) in 2010.
Drugs set to lose patent protection in the coming years include, Pfizer’s Detrol (tolterodine) in Septemeber 2012, Johnson & Johnson’s Doribax in 2015 and Glaxosmithkline’s Avodart in 2015.
The current urological disorders pipeline does offer some promising novel products, namely URG101, YM178, NX-1207, PRX302 and PSD597, indicated for different segments of the market.
However, revenue generated from these products is not expected to balance revenue losses incurred from patent expiries, and the market is expected to show slow growth in the forecast period.
Mergers and acquisitions have become popular in the urological disorders market, with increased participation from smaller companies able to rival leading corporations through co-operating with one another.
This has led to the decline experienced in recent years by 2010 market leaders Johnson & Johnson and Pfizer.
The global urological disorders market was estimated to be worth $8.1 billion in 2010, following a Compound Annual Growth Rate (CAGR) of 7.9 percent during 2002-2010, and is forecast to increase at a lower CAGR of 3.4 percent in the future to exceed $10 billion by 2017.
The Healthcare Global magazine is now available on the iPad. Click here to download it.
Dexcom: changing the lives of people with type 1 diabetes
It is estimated that 9.3% of adults around the world are living with type 1 diabetes, which amounts to a total of 463 million people. A further 1.1 million children and adolescents under the age of 20 are living with the condition.
Unlike the more prevalent type 2 diabetes, where the body still produces insulin and symptoms develop slowly, people with type 1 diabetes need regular insulin injections or pumps, and must monitor their sugar levels frequently.
In recent years a number of remote glucose monitoring systems have become available that patients can use at home. These work with a sensor, usually placed under the skin, that measures glucose levels every few minutes. This information is then transmitted wirelessly to a device like a smartphone or tablet, which can then be shared with their clinician.
British actress Nina Wadia's son Aidan, 14, has type 1 diabetes, and has been managing his condition using Dexcom, a glucose monitoring system used by patients all over the world. Here Wadia explains how Dexcom has improved their lives.
As a parent of someone with type 1 diabetes, what is your day-to-day life like?
Being able to take a breath, think and pivot constantly without getting frustrated becomes an essential mindset because sometimes it feels like each day is determined to be different from the day before. Whatever worked yesterday is going to misfire today.
Which areas of yours and Aidan’s life are most impacted by diabetes?
The one thing that you have to fight hard to reclaim is spontaneity, especially when it comes to food and exercise. It’s only when this is taken do you realise how essential each one is. You can be flexible and there are no real limits, but only in the sense that a great athlete can be flexible without limits because they’ve trained super hard to be that way. So we’ve all had to become athletes when it comes to being spontaneous.
How has Dexcom helped you and Aidan?
Dexcom has brought future science fiction to real life today. The continuous glucose monitoring system is tiny, sits discreetly on his body and gives him a ten-day breather between sensor changes, so it's goodbye finger-pricking seven times daily.
Dexcom is totally active at a grass roots level and for Diabetes Awareness has pledged to donate £2,000 if #DexcomDiabetesStories and/or #DexcomWarriorStories is shared 200 times! I’ll be sharing more on social media and would love to hear how other families are winning their fights.
Maybe most importantly Dexcom is trying to introduce a reimbursement programme for type 1 diabetes patients which will give greater access to modern, life changing hi-tech. I want to spread the word on the importance of accessing it through this campaign.
If you compared your life today with how it was before Aidan was using Dexcom, what has changed?
It's always working, which lets him take his mind off diabetes for longer stretches. It also lets me get off his back. We both receive alerts so I no longer have to pester him by asking him what his number is, and especially importantly, I don’t have to wake him at night to prick his finger if I’m worried. Dexcom gave us back our sleep!